Skip to main content
Clinical Trials/EUCTR2011-002175-42-AT
EUCTR2011-002175-42-AT
Active, not recruiting
Not Applicable

The effect and safety of dexmedetomidine as an additive to ropivacaine for interscalene brachial plexus blocks for shoulder surgery

Paracelsus Medizinische Universität - Universitätsklinik für Anästhesie0 sitesSeptember 5, 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
The goal of the present study is to investigate the safety and efficiacy of dexmedetomidine added toropivacaine for interscalene brachial plexus nerve block for shoulder surgery in humans.Provided the initial safety can be established, the trial will continue to evaluate secondary goalsincluding the duration of analgesia, onset of sensory and motor blockade, and opioid-inducedside effects. Tertiary outcomes will include activity, sleep, and subject satisfaction.
Sponsor
Paracelsus Medizinische Universität - Universitätsklinik für Anästhesie
Status
Active, not recruiting
Last Updated
13 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 5, 2011
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Paracelsus Medizinische Universität - Universitätsklinik für Anästhesie

Eligibility Criteria

Inclusion Criteria

  • ASA I\-III adult subjects
  • Elective shoulder surgery
  • Plan for interscalene brachial plexus block combined with general anesthesia
  • Interscalene block placed between 7:00 a.m. and 12:00 a.m.
  • Willingness to be contacted postoperatively for brief (5\-10 min) phone call
  • questionnaires
  • Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes

Exclusion Criteria

  • Age \< 18
  • Age \> 65
  • Inability to understand protocol due to language barrier
  • Coagulation/bleeding disorders
  • Chronic pain requiring daily opioids \> 15 mg oral morphine equivalents (equals oral
  • usage of \> 10 mg oxycodone/daily; \> 5 mg methadone/day; \> 4 mg hydromorphone/day)
  • Moderate (NRS pain score \> 3\) daily average pain
  • Daily use of gabapentin, pregabalin, tricyclic antidepressant, serotonin\-norepinephrine
  • reuptake inhibitor, tramadol, corticosteroids
  • Hypersensitivity to amide local anesthetics

Outcomes

Primary Outcomes

Not specified

Similar Trials